ArticleFrontiers in urology2026
Microsatellite instability in penile cancer: comparative analysis of primary tumors and metastases.
Article in Frontiers in urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Penile cancer (PeCA) presents high morbidity and mortality and is more prevalent in underdeveloped countries. The presence of nodal metastasis at diagnosis or as early recurrence carries a worse prognosis, making it important to determine whether clinically relevant biomarkers are maintained between primary tumors and corresponding lymph node metastases. We aim to describe the presence of DNA microsatellite instability (MSI) in primary PeCA tumors and locoregional lymph nodes affected by metastatic cells, as well as to assess HPV status through p16 expression. Methods: A total of 116 patients were comparatively evaluated between the primary tumor and lymph node metastases. The evaluation of p16 and mismatch repair proteins was done by immunohistochemistry, and MSI status was assessed using a hexa-plex marker by polymerase chain reaction, followed by fragment analysis. Results: All patients underwent a standard lymphadenectomy (inguinal or pelvic), with a pN0 frequency of 33.6%. MSI-H was found in three patients (2.6%), with correspondence between the presence of the biomarker in the primary tumors and the lymph node metastases. A second validation was performed using IHC for MMR, with MLH1/PMS2 loss in MSI-H cases. 22.8% of patients expressed p16 by immunohistochemistry. p16 positivity was associated with a 55% reduction in the risk of death. All MSI-H patients were p16 positive. Conclusion: MSI-H occurs in 2,6% of the sample and is associated predominantly with MLH1/PMS2 loss and p16 positivity. Together, these findings suggest potential interactions between HPV- associated carcinogenesis and genomic instability. Further prospective, biomarker-driven trials are warranted to define their prognostic and therapeutic relevance in PeCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.